DURHAM–Grid Therapeutics, which is already headed to clinical trials of an anti-cancer immunology treatment, has raised $1.9 million of a combined equity/debt round aimed at $5 million, according to a regulatory filing.
According to the filing, seven investors participated in this round so far. The company raised $4.5 million n 2018.
Grid was established in 2016, based on research at Duke. The FDA has approved its investigational new drug (IND) application for GT103 to treat solid tumors. The approval means Grid can begin a Phase 1 clinical trial to investigate the therapy to treat patients with refractory – or recurring – non-small cell lung cancer.
Grid licensed the exclusive global rights to GT103 from Duke to develop the first human-derived antibody as a targeted immunotherapy for cancer. The therapy is based on an antibody that inhibits Complement Factor H (CFH), a protein that protects cancer cells.
A graphic from Grid Therapeutics describes its technology.
The company is using its immunotherapy platform to develop a pipeline of human-derived, tumor-targeted antibodies to treat a variety of cancers.
FDA clears tests of Durham startup Grid Therapeutics’ cancer immunotherapy
